Fortress Biotech, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| Cost of revenue | $20.9M | $20.9M | $22.9M | $30.8M | $32.1M |
| Selling, general & administrative | $96.4M | $87.7M | $91.0M | $113.7M | $86.8M |
| Research and development | $11.9M | $56.6M | $106.1M | $134.9M | $128.9M |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M | -$188.5M |
| Pretax income | -$33.5M | -$120.5M | -$153.6M | -$213.5M | -$164.4M |
| Income tax expense | -$620,000 | $312,000 | $521,000 | $449,000 | $473,000 |
| Net income | $6.8M | -$46.0M | -$60.6M | -$86.6M | -$64.7M |
| Balance Sheet | |||||
| Cash and equivalents | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M |
| Current assets | $123.8M | $90.4M | $117.0M | $230.4M | $346.5M |
| Total assets | $185.5M | $144.2M | $167.5M | $294.3M | $396.5M |
| Current liabilities | $49.7M | $71.4M | $84.9M | $127.7M | $101.0M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M |
| Total debt | — | — | — | — | $60.5M |
| Stockholders' equity | $49.9M | $22.7M | $22.5M | $41.7M | $108.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$65.8M | -$80.2M | -$128.2M | -$179.4M | -$116.5M |
| Depreciation and amortization | $403,000 | $1.0M | $2.2M | $3.1M | $2.6M |
| Stock-based compensation | $28.7M | $32.6M | $17.0M | $23.0M | $19.5M |
| Capital expenditure | — | $0 | $63,000 | $2.7M | $4.6M |
| Free cash flow | — | -$80.2M | -$128.3M | -$182.1M | -$121.1M |
| Dividends paid | $664,000 | $694,000 | $736,000 | $749,000 | $749,000 |
| Impairments | $0 | $3.7M | $3.1M | $0 | $0 |
Shares outstanding 33.2M · Free float 45.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.